Uy Ear
Stock Analyst at Mizuho
(3.21)
# 1,011
Out of 4,858 analysts
62
Total ratings
47.22%
Success rate
15.23%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $20 → $23 | $22.20 | +3.60% | 11 | May 19, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $25.16 | +237.84% | 2 | May 15, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $20 → $21 | $13.89 | +51.19% | 14 | Feb 26, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $16.34 | +22.40% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.79 | +26.23% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $31.07 | +28.74% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $6.99 | +128.90% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $11.00 | +263.64% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $39.07 | +358.15% | 5 | May 17, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $9.87 | +133.03% | 3 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $116 → $140 | $124.77 | +12.21% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $156.45 | -74.43% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.35 | +325.53% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.13 | +165.49% | 2 | Mar 1, 2023 | |
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $22.20
Upside: +3.60%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $25.16
Upside: +237.84%
Arcutis Biotherapeutics
Feb 26, 2025
Maintains: Outperform
Price Target: $20 → $21
Current: $13.89
Upside: +51.19%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $16.34
Upside: +22.40%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.79
Upside: +26.23%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $31.07
Upside: +28.74%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $6.99
Upside: +128.90%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $11.00
Upside: +263.64%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $39.07
Upside: +358.15%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $9.87
Upside: +133.03%
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $124.77
Upside: +12.21%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $156.45
Upside: -74.43%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.35
Upside: +325.53%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.13
Upside: +165.49%